TransCode Therapeutics, Inc.
Sue Duggan, RN MBA, has an extensive background in various companies within the healthcare industry, holding titles such as Senior Vice President, Vice President, Director, Manager, and Emergency Medical Technician. Sue has experience in clinical operations, project management, clinical affairs, program management, and office management. Sue earned their Master of Business Administration (MBA) from Rivier University, an ADN in Nursing from Northern Essex Community College, and a BS from Colby Sawyer College.
This person is not in any teams
TransCode Therapeutics, Inc.
TransCode Therapeutics is an emerging RNA oncology company committed to defeating cancer through the intelligent design and effective delivery of RNA therapeutics. Our lead therapeutic candidate, that we believe has blockbuster potential, targets an RNA molecule which has been shown to be the driver of metastatic disease across multiple tumor typesand has been validated pre-clinically in our lab at MGH. Our initial FIH clinical study, for which an eIND filing is planned for Q1 of 2022, is intended to provide positive proof-of-mechanism for the TTX platform.